Bibliography
- Kohler G , MilsteinC: Continuous cultures of fused cells secreting antibody of predefined specificity.Nature256 , 495–497 (1975).
- Jones PT , DearPH, FooteJ, NeubergerMS, WinterG: Replacing the complementarity-determining regions in a human antibody with those from a mouse.Nature321 , 522–525 (1986).
- Morrison SL , JohnsonMJ, Herzenberg LA, Oi VT: Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA81 , 6851–6855 (1984).
- Reichert JM , RosensweigCJ, FadenLB, DewitzMC: Monoclonal antibody successes in the clinic.Nat. Biotechnol.23 , 1073–1078 (2005).
- Krejsa C , SadeeW, RoggeM: Protein therapeutics: new applications for pharmacogenetics.Nat. Rev. Drug Discov.5 , 507–521 (2006).
- Yan L , BeckmanRA: Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.Biotechniques39 , 565–568 (2005).
- Carter P : Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer1 , 118–129 (2001).
- Cartron G , DacheuxL, SallesG et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptorFcγRIIIa gene. Blood99 , 754–758 (2002).
- Wu J , EdbergJC, RedechaPB et al.: A novel polymorphism of FcgRIIIa (CD16) alters receptor function and predisposes to autoimmune disease.J. Clin. Invest.100 , 1059–1070 (1997).
- Koene HR , KleijerM, AlgraJ et al.: FcgRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the Fc γRIIIa-48L/R/H phenotype.Blood90 , 1109–1114 (1997).
- Weng WK , LevyR: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.J. Clin. Oncol.21 , 3940–3947 (2003).
- Dall’Ozzo S , TartasS, PaintaudG et al.: Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration–effect relationship. Cancer Res.64 , 4664–4669 (2004).
- Treon SP , HansenM, BranaganAR et al.: Polymorphisms in FcgRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom’s macroglobulinemia.J. Clin. Oncol.23 , 474–481 (2005).
- Farag SS , FlinnIW, ModaliR et al.: FcgRIIIa and FcgRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia.Blood103 , 1472–1474 (2004).
- Lin TS , FlinnIW, ModaliR et al.: FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.Blood105 , 289–291 (2005).
- Cheung NK , SowersR, VickersAJ et al.: FCGR2A polymorphism is correlated with clinical outcome following immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.J. Clin. Oncol.24 , 2885–2890 (2006).
- Louis E , El Ghoul Z, Vermeire S et al.: Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn’s disease. Aliment. Pharmacol. Ther.19 , 511–519 (2004).
- Yeon CH , PegramMD: Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.Invest. New Drugs23 , 391–409 (2005).
- Mugnier B , BalandraudN, DarqueA et al.: Polymorphism at position -308 of the tumor necrosis factor-α gene influences outcome of infliximab therapy in rheumatoid arthritis.Arthritis Rheum.48 , 1849–1852 (2003).
- Fonseca JE , CarvalhoT, CruzM et al.: Polymorphism at position -308 of the tumour necrosis factor α gene and rheumatoid arthritis pharmacogenetics.Ann. Rheum. Dis.64 , 793–794 (2005).
- Louis E , VermeireS, RutgeertsP et al.: A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.Scand. J. Gastroenterol.37 , 818–824 (2002).
- Diller W : Problems with biomarkers: a tale of three drugs.In vivo: The Business and Medicine Report19 , 31–45 (2005).
- Cunningham D , HumbletY, SienaS et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.N. Engl. J. Med.351 , 337–345 (2004).
- Saltz LB , MeropolNJ, LoehrerPJ Sr et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol.22 , 1201–1208 (2004).
- Burtness B , GoldwasserMA, FloodW, MattarB, ForastiereAA: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.J. Clin. Oncol.23 , 8646–8654 (2005).
- Moroni M , VeroneseS, BenvenutiS et al.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.Lancet Oncol.6 , 279–286 (2005).
- Bergsland EK : When does the presence of the target predict response to the targeted agent?J. Clin. Oncol.24 , 213–216 (2006).
- Vallbohmer D , ZhangW, GordonM et al.: Molecular determinants of cetuximab efficacy.J. Clin. Oncol.23 , 3536–3544 (2005).
- Nagata Y , LanKH, ZhouX et al.: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.Cancer Cell6 , 117–127 (2004).
- Lequerre T , Gauthier-JauneauAC, Bansard C et al.: Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res. Ther.8 , R105 (2006).
- Guttman S , KesslerG: The US Food and Drug Administration perspective on cancer biomarker development.Nat. Rev. Camcer6 , 565–571 (2006).